Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
Chronic myeloid leukemia
allogeneic stem cell transplant
tyrosine kinase inhibitors
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
15
7
2020
medline:
24
4
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;
Identifiants
pubmed: 32662346
doi: 10.1080/10428194.2020.1783444
pmc: PMC8424781
mid: NIHMS1701212
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2811-2820Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NHLBI NIH HHS
ID : U10 HL069294
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Br J Haematol. 2000 Jun;109(4):722-8
pubmed: 10929021
Int J Hematol. 2007 Oct;86(3):275-81
pubmed: 17988996
Med Decis Making. 1993 Oct-Dec;13(4):322-38
pubmed: 8246705
Semin Hematol. 2003 Jan;40(1):79-86
pubmed: 12563614
Blood. 2009 Nov 12;114(20):4361-8
pubmed: 19729517
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
Blood. 2003 May 15;101(10):3794-800
pubmed: 12560227
N Engl J Med. 2001 Apr 5;344(14):1031-7
pubmed: 11287972
Cancer. 2017 Aug 1;123(15):2875-2880
pubmed: 28387926
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
J Clin Oncol. 2003 Jun 1;21(11):2138-46
pubmed: 12775739
Blood. 2002 Oct 1;100(7):2292-302
pubmed: 12239137
Blood. 2010 Dec 16;116(25):5497-500
pubmed: 20833982
Cancer. 2006 Mar 15;106(6):1306-15
pubmed: 16463391
Health Serv Res. 1994 Feb;28(6):771-84
pubmed: 8113057
Blood. 2002 Mar 15;99(6):1928-37
pubmed: 11877262
Blood. 2011 Jan 27;117(4):1141-5
pubmed: 21098399
Blood. 1993 Aug 1;82(3):691-703
pubmed: 8338938
Lancet Haematol. 2015 May;2(5):e186-93
pubmed: 26688093
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
N Engl J Med. 2001 Apr 5;344(14):1038-42
pubmed: 11287973
Blood. 2003 Jan 15;101(2):441-5
pubmed: 12393604
Lancet. 1984 Mar 24;1(8378):665-8
pubmed: 6142357